You are here

Article Text

Article menu
Download PDFPDF
ABN Abstracts 2022
Poster presentations
113 Assessing predictors of NEDA in RRMS patients initiating dimethyl fumarate in a real-world setting
  1. Sarmad Al-Araji1,
  2. Alessia Bianchi1,
  3. Arman Eshaghi1,
  4. Le Zhang1,
  5. Baris Kanber2,3,
  6. Ashwani Jha2,4,
  7. Olivia Goodkin1,3,
  8. Frederik Barkhof1,2,3,5,
  9. Parashkev Nachev2,4,
  10. Olga Ciccarelli1,2
  1. 1Queen Square MS Centre, Department of Neuroinflammation, UCL Institute of Neurology
  2. 2NIHR UCLH Biomedical Research Centre, UCL Queen Square Institute of Neurology
  3. 3Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, UCL
  4. 4High-Dimensional Neurology Group, Department of Brain Repair and Rehabilitation, UCL
  5. 5Department of Radiology and Nuclear Medicin, VU University Medical Centre, Amsterdam, The Netherland

Abstract

Introduction No evidence of disease activity (NEDA) is a treatment goal when using disease modifying therapy for treating relapsing remitting multiple sclerosis (RRMS).1 However, predicting which patients may achieve NEDA is challenging.

Objective To identify the baseline clinical and MRI features that predict NEDA in patients initiating dimethyl fumarate (DMF).

Method: In our observational study, we retrospectively collected clinical and radiological data acquired for patients with RRMS initiating DMF. Demographics and clinical details at MS onset and at DMF initiation (baseline) were evaluated. We investigated the associations between all the baseline clinical and MRI findings and NEDA at 24 months using a combined multiple logistic regression.

Results We had a total of 670 patients in our cohort and only 339 (50%) achieved NEDA at 24 months. Lower EDSS (Log odds[95%CI]= -0.19[-0.30 to -0.03], p=0.01), lower number of new MRI lesions at baseline (Log odds[95%CI]= -0.14[-0.32 to -0.04], p=0.01) and lower number of relapses in the previous 12 months (Log odds[95%CI]= -0.39[-0.77 to -0.26], p=0.0001) significantly predicted NEDA at 24 months.

Conclusion Significant predictors for achieving NEDA were the number of relapses in the previous year, the number of new MRI lesions and the EDSS at DMF initiation. This could be useful in clinical practice to counsel patients regarding their potential response to DMF.

https://doi.org/10.1136/jnnp-2022-abn2.157

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.